國家衛生研究院 NHRI:Item 3990099045/9996
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 909132      Online Users : 852
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/9996


    Title: Invalidation of atorvastatin patent highlights complex Chinese patent law
    Authors: Chen, FC;Yeh, KL
    Contributors: Division of Biostatistics and Bioinformatics
    Abstract: Pfizer's atorvastatin (Lipitor) is a blockbuster drug for the treatment of cardiovascular diseases. In China, a critical polymorph patent of this drug has been recently invalidated by the Supreme People's Court for insufficiency of disclosure. Here, we discuss the particularities in patent litigation in China worth attention from the community.
    Date: 2016-11
    Relation: Trends in Pharmacological Sciences. 2016 Nov;37(11):883-886.
    Link to: http://dx.doi.org/10.1016/j.tips.2016.08.004
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0165-6147&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000386982700001
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84992640391
    Appears in Collections:[Feng-Chi Chen] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    PUB27659855.pdf443KbAdobe PDF422View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback